Outcome measures | FEX vs. 1st gen AH | FEX vs. 2nd gen AH | FEX vs. PL | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Included studies | number | Heterogeneity (%) | P | Included studies | number | Heterogeneity (%) | P | Included studies | number | Heterogeneity (%) | P | ||
Antihistamine effects | Inhibition rate of wheal | Â | Â | Â | Â | 5 | 130 | 99 | 0.210 | 5 | 104 | 8 | <0.001 |
Inhibition rate of flare |  |  |  |  | 4 | 100 | 100 | 0.840 | 5 | 176 | 96 | < 0.001 | |
Safety profiles | AE | 10 | 522 | 0 | 0.031 | 22 | 5699 | 0 | 0.890 | 37 | 8591 | 0 | 0.987 |
SE | 10 | 522 | 0 | 0.046 | 27 | 6471 | 0 | 0.002 | 38 | 8700 | 0 | 0.120 | |
CFF | 6 | 232 | 98 | <0.001 | 3 | 118 | 89 | 0.280 | 6 | 232 | 85 | 0.170 | |
CRT | 7 | 254 | 97 | <0.001 | 4 | 140 | 76 | 0.220 | 6 | 206 | 89 | 0.280 | |
CTT | 3 | 92 | 98 | 0.040 | 3 | 92 | 48 | <0.001 | 3 | 92 | 95 | 0.960 | |
LARS | 7 | 272 | 99 | 0.003 | 3 | 118 | 96 | 0.002 | 7 | 272 | 90 | <0.001 | |
VAS of drowsiness | 2 | 102 | 0 | <0.001 | Â | Â | Â | Â | 3 | 116 | 97 | 0.070 |